Home
About Us
Who we are
Founders and Chairs
Individual Members
Emeritus Members
Corporate and Research Members
Cambridge Angels Team
Infographic
Entrepreneurs
Why Cambridge Angels?
Is Angel Investing right for you?
Investment Criteria
Application Process
Apply
Angels
Membership Information
Member portal
Angel Interviews
Portfolio
Current Portfolio
Exits
Cambridge Angels Founded Companies
Portfolio facts
Portfolio Interviews
Apply to Cambridge Angels
News
Portfolio News
Ecosystem News

Welcome to the Cambridge Angels

Home
About Us
Who we are
Founders and Chairs
Individual Members
Emeritus Members
Corporate and Research Members
Cambridge Angels Team
Infographic
Entrepreneurs
Why Cambridge Angels?
Is Angel Investing right for you?
Investment Criteria
Application Process
Apply
Angels
Membership Information
Member portal
Angel Interviews
Portfolio
Current Portfolio
Exits
Cambridge Angels Founded Companies
Portfolio facts
Portfolio Interviews
Apply to Cambridge Angels
News
Portfolio News
Ecosystem News
Monument Therapeutics announces the grant of U.S. patent supporting MT1988 program for schizophrenia
4 January 2024
Guest User
Monument Therapeutics announces the grant of U.S. patent supporting MT1988 program for schizophrenia
Guest User
4 January 2024

Monument Therapeutics announces the grant of U.S. patent supporting MT1988 program for schizophrenia

Guest User
4 January 2024
Newer PostQureight founder: Pitching to investors is energising once you take the plunge
Older PostSphere Fluidics appoints Dr. Graeme Daniels as Vice President of Sales and Marketing
LI-In-Bug_small.png
Back to Top
Privacy
info@cambridgeangels.net